ストックスクリーナーアプリを入手
2.30
14.71%
-0.42
アフターアワーズ：
2.30
前日終値:
$2.72
開ける：
$2.66
24時間の取引高:
171.84K
Relative Volume:
4.49
時価総額：
$32.79M
収益：
$52.16M
当期純損益:
$-48.60M
株価収益率:
-2.5275
EPS:
-0.91
ネットキャッシュフロー:
$-77.48M
1週間 パフォーマンス:
-26.11%
1か月 パフォーマンス:
-41.85%
6か月 パフォーマンス:
-72.93%
1年 パフォーマンス:
-49.55%
1日の値動き範囲:
$2.19
$2.75
1週間の範囲:
$2.19
$3.25
52週間の値動き範囲:
$2.19
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
名前
Hookipa Pharma Inc
セクター
電話
0114318906360
住所
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| HOOK | 2.30 | 32.79M | 52.16M | -48.60M | -77.48M | -0.91 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-11-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-03 | 開始されました | Truist | Buy |
| 2020-10-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-19 | 再開されました | H.C. Wainwright | Buy |
| 2019-09-27 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-13 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Hookipa Pharma Inc (HOOK) 最新ニュース
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com UK
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - Quantisnow
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
Hookipa Pharma Inc (HOOK) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):